Breaking News

WuXi STA Opens Large-Scale Oligonucleotide Mfg. Facility

State-of-the-art facility expands capacity and capability for this novel modality, providing services from preclinical to commercial.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, has opened its large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in Changzhou, China. This milestone marks WuXi STA’s establishment of a comprehensive platform to support the process R&D and manufacture of oligonucleotide APIs from preclinical to commercial.   Nucleic acid drugs have gradually become a hot area in the global innovative drug industry and many nucleic acid drugs hav...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters